WO1991009052A1 - Chromogenic substrate - Google Patents

Chromogenic substrate Download PDF

Info

Publication number
WO1991009052A1
WO1991009052A1 PCT/SE1990/000797 SE9000797W WO9109052A1 WO 1991009052 A1 WO1991009052 A1 WO 1991009052A1 SE 9000797 W SE9000797 W SE 9000797W WO 9109052 A1 WO9109052 A1 WO 9109052A1
Authority
WO
WIPO (PCT)
Prior art keywords
gly
lys
pna
lle
arg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/SE1990/000797
Other languages
French (fr)
Inventor
Salo Arielly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KABI DIAGNOSTICA AB
Pfizer Health AB
Original Assignee
KABI DIAGNOSTICA AB
Kabi Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KABI DIAGNOSTICA AB, Kabi Pharmacia AB filed Critical KABI DIAGNOSTICA AB
Priority to DE69030102T priority Critical patent/DE69030102T2/en
Priority to JP3501386A priority patent/JP2929555B2/en
Priority to US07/859,717 priority patent/US5334703A/en
Priority to EP91900986A priority patent/EP0505428B1/en
Publication of WO1991009052A1 publication Critical patent/WO1991009052A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention relates to a new chromogenic synthetic substrate used for quantitative determination of bacterial endotoxins in physiological fluids, food, pharmaceuticals etc.
  • Bacterial endotoxins are produced by Gram negative bacteria and are considered by most investigators to be a very important factor in the development of septecemia.
  • Several methods for determination of endotoxin have been described based on the observation by Levin and Bang (1956) that endotoxins specifically activate the clotting system of Limulus Polyphemus.
  • LAL Limulus Amebocyte Lysate
  • A.E. Torano et al have disclosed that an enzyme from Limulus amebocyte lysate shows similar specificity to mammalian blood coagulation factor X a (Thrombosis Research 34, 407-417, 1984), which recognize the sequence -lle-Glu-Gly-Arg- in its natural substrate prothrombin.
  • the carboxy terminal should be -Ala-Arg- or -Cys- Arg- and this substrate has given relative activity which is as good as or a little better than standard -Gly-Arg-. Due to the complicated mechanism in these reactions it is not possible to know which peptide sequence could give an acceptable result.
  • Glyc Glycolic acid
  • the chromogenic synthetic peptide or peptide isostere derivative in the present invention shows high sensitivity in the method used for the determination of endotoxins.
  • the new substrates are characterized by the following formula: R-i - A-- - A2 - A3 - A4 - R2 or its salt
  • the present invention also discloses the process for the preparation of the peptid derivatives.
  • R* ⁇ H or a protective group
  • A1 H, He, Leu or Val
  • a 2 Glu, Asp, Ser, Thr
  • A3 Gly or Glyc
  • a 4 Arg or Lys
  • R2 an aromatic or heterocyclic group which gives the compound
  • R2-NH2 are prior known compounds with chromogenic properties which permit quantifying of endotoxins by determination of splitted marker directly or after derivatization (H.C. Hemker: Loc. cit.) with the proviso that A3 is Gly when A4 is Lys and that A3 is Glyc when A4 is Arg.
  • Example of compounds which could be R2-NH- 2 are: p-nitroaniline, 3-carboxy- 4-hydroxyaniline, 3-sulfo-4-nitroaniline, 3-alkoxy-4-nitroaniline, 3-carboxy- 4-nitroaniline, 4-methyloxy-naphtylamine, 4-(N-ethyl-N-hydroxyethyl) aminoaniline, 5-amino-isophtalic acid-dimethyl ester, 5-amino-8-nitroquinoline, 7-amino-4-trifluormethyl coumarine, 7-amino-4-methyl coumarine, 4-ami ⁇ o- diphenylamine.
  • the invention also discloses the use of these derivatives for determination of bacterial endotoxins.
  • the new peptide or peptide isostere derivatives contain as carboxyterminal Lys when combined with Gly and Arg when combined with Glyc.
  • the combination Gly-Lys was considered unfavourable until present in substrates used for Limulus amebocyte lysate and the combination Glyc-Arg has never been used in this type of substrates before in methods for determination of bacterial endotoxins. Description of synthesis
  • the free amino acid or peptide is indicated by H- at the N-terminal amino group and -OH at the carboxy terminal group.
  • the amino group is always given to the left and the carboxy to the right.
  • a reagent (100 ⁇ l) consisting of a mixture of LAL (50% of the clotting concentration) and the chromogenic substrate (4.4 mM) in a Tris buffer of pH 7.9 is added to an equal volume of the sample.
  • the resulting reaction (activation of the LAL and the subsequent hydrolyses of the chromogenic substrate) is carried out at 37°C. After 15 min. the reaction is terminated by the addition of 400 ⁇ l of acetic acid and the absorbance is read at 405 nm.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Luminescent Compositions (AREA)

Abstract

The invention relates to novel peptide derivatives with the formula: R1-A1-A2-A3-A4-R2 or its salt, wherein R1 = H or a protective group; A1 = H, Ile, Leu or Val; A2 = Glu, Asp, Ser, Thr; A3 = Gly or Glyc; A4 = Arg or Lys; R2 = 4-nitro aniline with the proviso that A3 is Gly when A4 is Lys and that A3 is Glyc when A4 is Arg. The invention also discloses the process for the preparation of the peptide derivatives, the method for the determination of the bacterial endotoxins by the use of the invented peptide derivatives and the use of these derivatives for determination of bacterial endotoxins.

Description

Chromogenic substrate
Field of the invention
The present invention relates to a new chromogenic synthetic substrate used for quantitative determination of bacterial endotoxins in physiological fluids, food, pharmaceuticals etc.
The background of the invention
Bacterial endotoxins are produced by Gram negative bacteria and are considered by most investigators to be a very important factor in the development of septecemia. Several methods for determination of endotoxin have been described based on the observation by Levin and Bang (1956) that endotoxins specifically activate the clotting system of Limulus Polyphemus. In the beginning a test, in which Limulus Amebocyte Lysate (LAL) in contact with endotoxins containing sources, produce a specific gelation, had been developed. More recently chromogenic and fluorogenic methods based on the above observation have been developed and can rapidly detect small amounts of endotoxins (H.C. Hemker: Handbook of Synthetic Substrates, 1983, Martinus Nijhoff Publisher, Boston).
Prior art
A.E. Torano et al have disclosed that an enzyme from Limulus amebocyte lysate shows similar specificity to mammalian blood coagulation factor Xa (Thrombosis Research 34, 407-417, 1984), which recognize the sequence -lle-Glu-Gly-Arg- in its natural substrate prothrombin.
Other investigations have also shown the important role the COOH-terminal Gly- Arg sequence plays when analysing endotoxin. T. Harada et al, Biomedical Applications of the Horseshoe Crab (Limulidal), E. Cohen (ed), Alan R. Liss Inc. New York, 1979, pages 209-220, disclose in a table on page 213 different substrates which are used, but only those having the carboxy termial sequence Gly-Arg give interesting results. On page 212, lines 7-10 from the bottom, the authors point out: "These results clearly indicate that Limulus clotting enzyme displays a high specificity towards the peptide pNA having COOH-terminal Gly- Arg sequence". US 4 188 264 and US 4 576 745 also give Gly-Arg as carboxy-terminal sequence in the substrate used for determination of endotoxin. Other substrates have been investigated, all of them showing Arg as carboxy terminal.
According to US 4 406 832 the carboxy terminal should be -Ala-Arg- or -Cys- Arg- and this substrate has given relative activity which is as good as or a little better than standard -Gly-Arg-. Due to the complicated mechanism in these reactions it is not possible to know which peptide sequence could give an acceptable result.
Surprisingly and against the prior art within the field, we have now found that a substrate which has the carboxy terminal sequence -Gly-Lys- gives a relative activity which is at least 20% better compared with known substrates.
The use of Glycolic acid (Glyc) in a substrate for determination of endotoxin has never been disclosed before, and it is very surprising that the effect is as good when using -Glyc-Arg- as when using Gly-Lys, both of them giving a better effect than the normally used Gly-Arg.
Description of the invention
The chromogenic synthetic peptide or peptide isostere derivative in the present invention shows high sensitivity in the method used for the determination of endotoxins.
The new substrates are characterized by the following formula: R-i - A-- - A2 - A3 - A4 - R2 or its salt
Figure imgf000004_0001
with the proviso that A3 is Gly when A4 is Lys and that A3 Is Glyc when A4 is Arg. The present invention also discloses the process for the preparation of the peptid derivatives.
It also discloses the method for determination of bacterial endotoxins by the use of the derivative with the following formula:
Ri - Ai - A2 - A3 - A4 - R2 or its salt where
R*ι = H or a protective group
A1 = H, He, Leu or Val
A2 = Glu, Asp, Ser, Thr
A3 = Gly or Glyc
A4 = Arg or Lys
R2 = an aromatic or heterocyclic group which gives the compound
R2-NH2 by enzymatic hydrolysis
R2-NH2 are prior known compounds with chromogenic properties which permit quantifying of endotoxins by determination of splitted marker directly or after derivatization (H.C. Hemker: Loc. cit.) with the proviso that A3 is Gly when A4 is Lys and that A3 is Glyc when A4 is Arg.
The use of these derivatives for determination of bacterial endotoxins is also disclosed.
Example of compounds which could be R2-NH-2 are: p-nitroaniline, 3-carboxy- 4-hydroxyaniline, 3-sulfo-4-nitroaniline, 3-alkoxy-4-nitroaniline, 3-carboxy- 4-nitroaniline, 4-methyloxy-naphtylamine, 4-(N-ethyl-N-hydroxyethyl) aminoaniline, 5-amino-isophtalic acid-dimethyl ester, 5-amino-8-nitroquinoline, 7-amino-4-trifluormethyl coumarine, 7-amino-4-methyl coumarine, 4-amiπo- diphenylamine. The invention also discloses the use of these derivatives for determination of bacterial endotoxins.
The new peptide or peptide isostere derivatives contain as carboxyterminal Lys when combined with Gly and Arg when combined with Glyc. The combination Gly-Lys was considered unfavourable until present in substrates used for Limulus amebocyte lysate and the combination Glyc-Arg has never been used in this type of substrates before in methods for determination of bacterial endotoxins. Description of synthesis
Conventional techniques for coupling and conventional protecting groups (Z, Boc etc) used within the peptide chemistry (M. Bodanzsky: Principles of Peptide Synthesis, Springer Verlag 1984) e.g. addition step-by-step of the amino acids at the C-terminal amino acid provided with a marker or synthesis of the N- terminal peptide fragment per se, which then is coupled to the C-terminal amino acid provided with a marker, have been used.
The synthesis of different substrates according to the invention will be discribed more in detail in the following not limited working examples.
Purification of the intermediates and end products were performed by precipitation, crystallization or gel filtration chromatography. The purified end products were lyophilized. Prefabricated glass plates of siiicagel F254 were used for TLC analyses. After terminated chromatography the plates were inspected in U.V. light (254 nm) and were developed thereafter with ninhydrine and chlorine/dicarboxidine reagent. The Rf value given are results from single chromatographies.
Used solvent system for TLC have been indicated according to the following table:
Figure imgf000006_0001
HPLC analysis were performed on Merck R.P. column (Hibar Lichracart) with 40% MeOH in 5% triethylaminophosphate pH 2.35 as eluent (1 ml/min). The optical activity of the end products were determined at 589 nm in 50% AcOH at a concentration of 0.4-1.0 g/100 ml at 25°C. The below mentioned abbreviations have the following meaning: (I.U.P.A.C. indication has been used were such exists).
Figure imgf000007_0001
Figure imgf000007_0002
All amino acids in the substrates have L-configurattion if not else is indicated.
The free amino acid or peptide is indicated by H- at the N-terminal amino group and -OH at the carboxy terminal group. The amino group is always given to the left and the carboxy to the right.
Figure imgf000007_0003
9 ml TFA is added to 10 mmol α-Boc-ε-Z-Lys-pNA dissolved in 25 ml methylenchloride. The solution is stirred for 30 minutes at room temperature and is precipitated with a mixture 2:1 of t-butylmethylether-petroleumether.
Yield 95%.
TLC: Rf = 0.60 (A). 1 b) α-Boc-Y-O-Bzl-Glu-Glv-OH Molecular weight = 394.4
To 0.1 mol H-Gly-OH dissolved in 200 ml 1 molar NaHCθ3 a solution of 0.1 mol of α-Boc-γ-O-Bzl-Glu-O-Su in 200 ml dioxan is added. The mixture is stirred overnight at room temperature. Next day the solution is evaporated in vacuo to an oily residue which is dissolved in 100 ml water and washed with diethylether. The water phase is brought to pH 2 with KHSO4 solution and extracted with EtOAc. After drying with
Na2S04, the EtOAc solution is evaporated and the substance precipitated with a mixture (1 :1 ) of diethylether-petroleumether.
Yield 85%.
TLC: Rf = 0.5 (Pa).
1c) H-γ-O-Bzl-Glu-Glv-OH FA Molecular weight = 408.4
.9 ml TFA is added to 10 mmol α-Boc-γ-O-Bzl-Glu-Gly-OH (1 b) dissolved in 20 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature, evaporated in vacuo to an oil and precipitated with diethylether. Yield: 90% TLC: Rf = 0.44 (A).
1d) -Boc-lle-^O-Bzl-Glu-Glv-OH Molecular weight = 507.6
To 0.1 mol H-γ-O-Bzl-Glu-Gly-OH FA dissolved in 250 ml 1 molar NaHC03 a solution of 0.1 mol α-Boc-lle-O-Su in 250 ml dioxan is added. The mixture is stirred overnight at room temperature. Next day the solution is evaporated in vacuo, the residue dissolved in 100 ml water and washed with EtOAc. The water phase is brought to pH 3 with KHSO4 solution and extracted with EtOAc. After drying with Na2S04 the EtOAc solution is evaporated and the substance precipitated with petroleumether. Yield: 92% TLC: Rf= 0.6 (Pa) 1e) -Boc-lle-γ-O-Bzl-Glu-Glv-ε-Z-Lvs-DNA Molecular weight = 890.0
3 mmol ε-Z-Lys-pNA FA (1a) dissolved in 25 ml DMF is neutralized in cold (- 10°C) with Et3N. To the solution 3 mmol α-Boc-lle-f O-Bzl-Glu-Gly-OH (1d), 3 mmol HOBT and 3.2 mmol DCCI are added. The mixture is stirred for 1 hour in cold and overnight at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil which is dissolved in EtOAc and is washed with 2% NaHCθ3, 2% KHSO4 and H20. After drying with with Na Sθ4, the EtOAc phase is evaporated and the substance is precipitated with diethylether. Yield: 61% TLC: Rf = 0.67 (Pi)
1f) α-Ac-lle-γ-O-Bzl-Glu-Glv-ε-Z-Lvs-DNA Molecular weight = 831.9
3.5 ml TFA is added to 1.2 mmol α-Boc-lle-γ-O-Bzl-Glu-Gly-ε-Z-Lys-pNA (1e) in 6 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and is precipitated with diethyleter. The dry substance is dissolved in 10 ml DMF and neutralized in cold (-10°C) with 160 μl Et3N. 140 μl acetic anhydride is added and the mixture is stirred for 1 hour in cold and 2 hours at room temperature. The solution is evaporated in vacuo to an oil and the substance is precipitated with water. Yield: 86% TLC: Rf = 0.45 (P1).
1 ) α-Ac-lle-Glu-Glv-Lvs-pNA-HCI " Molecular weight = 644.15
10 ml triflic acid is added to a cold (-10°C) suspension of 1 mmol α-Ac-lle-γ*-0- Bzl-Glu-Gly-Z-Lys-pNA- (1f) in 10 ml methylenchloride. The mixture is stirred for 50 minutes at room temperature and precipitated with diethylether. The dried substance is ion exchanged on a Sephadex® QAE-25 column, in chloride form with 50% ETOH as eluent and is purified on a Merck Lobar® prepacked column (Lichroprep.® RP-8-B) with 50% MeOH as eluent (2 ml/minute). The purified product is lyophilized. Yield: 42% TLC: Rf = 0.2 (Pae) HPLC: 98% purity [ α] 25 = -63.1° (C= 0.5%)
D
Example 2 ff-Ac-lle-Ser-Gly-Lys-pNA-HCl Molecular weight = 602.11
2a) (x-Boc-Glv-ε-Z-Lvs-pNA Molecular weight = 557.6
5 mmol ε-Z-Lys-pNATFA (prepared as described in example 1a) dissolved in 25 ml* DMF is neutralized in cold (-10°C) with Et3N. To the solution 5 mmol α-Boc- Gly-OH, 5 mmol HOBT and 5 mmol DCCI are added. The mixture is stirred for 1 hour in cold and overnight at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHCθ3, 2% KHSO4 and H20. After drying with Na2S04 the EtOAc phase is evaporated in vacuo and the substance is precipitated with diethylether as an oil which solidifies in vacuo. Yield: 73% TLC: Rf = 0.55 (Pi).
2b) α-Boc-O-Bzl-Ser-Glv-ε-Z-Lvs-pNA Molecular weight = 734.2
10 ml TFA is added to 5 mmol α-Boc-Gly-ε-Z-Lys-pNA (2a) dissolved in 20 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethyleter. The dry substance is dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et3N. To the solution 5 mmol - Boc-O-Bzl-Ser-OH, 5 mmol HOBT and 5.1 mmol DCCI are added. The mixture is stirred for 1 hour in cold and overnight at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHCθ3, 2% KHSO4 and H2O. After drying with Na2Sθ4 the EtOAc phase is evaporated and the substance is precipitated with diethylether as an oil which solidifies in vacuo. Yield: 86% TLC: Rf = 0.62 (Pi). 2c) -Boc-lle-O-Bzl-Ser-Glv-ε-Z-Lvs-pNA Molecular weight: = 848.0
10 ml TFA is added to 2 mmol α-Boc-O-Bzl-Ser-Gly-ε-Z-Lys-pNA (2b) dissolved in 20 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dry substance is dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et3N. To the solution 2 mmol α-Boc-lle-ONp is added. The mixture is stirred for 1 hour in cold and 48 hours at room temperature. The solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHC03, 2% KHSO4 and H20.- After drying with Na2Sθ4 the EtOAc phase is evaporated and the substance is precipitated with diethylether.
Yield: 72%
TLC: Rf = 0.62 (Pi).
2d) α-Ac-lle-O-Bzl-Ser-Glv-ε-Z-Lvs-pNA Molecular weight = 789.9
5 ml TFA is added to 1 mmol α-Boc-lle-O-Bzl-Ser-Gly-ε-Z-Lys-pNA (2c) dissolved in 10 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dry substance is dissolved in 10 ml DMF and neutralized in cold (-10°C) with 80 μl Et3N. 70 μl acetic anhydride is added ad the mixture is stirred for 1 hour in cold and 2 hours at room temperature. The solution is evaporated in vacuo to an oil and the substance is precipitated with water. Yield: 85% TLC: Rf = 0.55 (Pi).
2) α-Ac-lle-Ser-Glv-Lvs-pNA-HCI Molecular weight = 602.11
10 ml triflic acid is added to a cold (-10°C) suspension of 1 mmol α-Ac-lle-O-Bzl- Ser-Gly-ε-Z-Lys-pNA (2d) in 10 ml methylenchloride. The mixture is stirred for 50 minutes at room temperature and precipitated with diethylether. The product is ion exchanged and purified in the same way as in example 1.
Yield: 35%
Figure imgf000012_0001
HPLC: 97% purity.
|- α] 25 = -50.1° (c= 0.5%)
Example 3 α-Ac-lle-Thr-Glv-Lvs-DNA-HCI Molecular weight = 616.13
3a) -Boc-O-Bzl-Thr-Glv-ε-Lvs-pNA Molecular weight = 748.2
10 ml TFA is added to 5 mmol α-Boc-Gly-ε-Z-Lys-pNA (2a) dissolved in 20 mi methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dry substance is dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et3N. To the solution 5 mmol α-
Boc-O-Bzl-Thr-OH, 5 mmol HOBT and 5.1 mmol DCCI are added. The mixture is stirred for 1 hour in cold and overnight at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil, which is dissolved in
EtOAc and washed with 2% NaHCθ3, 2% KHS0 and H20. After drying with
Na2S04 the EtOAc phase is evaporated and the substance is precipitated with diethylether as an oil which solidifies in vacuo.
Yield: 51%
TLC: Rf = 0.65 (Pi).
3b) α-Boc-lle-O-Bzl-Thr-Glv-ε-Z-Lvs-pNA Molecular weight = 862.0
10 ml TFA is added to 2 mmol α-Boc-O-Bzl-Thr-Gly-ε-Z-Lys-pNA (3a) dissolved in 20 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dry substance is dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et3N. To the solution 2 mmol α-Boc-lle-ONp is added. The mixture is stirred for 1 hour in cold and 48 hours at room temperature. The solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHCθ3, 2% KHSO4 and H2O. After drying with Na2S04 the EtOAc phase is evaporated and the substance is precipitated with diethylether. Yield: 50% TLC: Rf = 0.7 (P1)
3c) α-Ac-lle-O-Bzl-Thr-Glv-ε-Z-Lvs-pNA Molecular weight = 803.9
5 ml TFA is added to 1 mmol α-Boc-lle-O-Bzl-Thr-Gly-ε-Z-Lys-pNA (3b) dissolved in 10 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dry substance is dissolved in 10 ml DMF and neutralized in cold (-10°C) with 80 μl
Et3N. 70 μl acetic anhydride is added and the mixture is stirred for 1 hour in cold
(-10°C) and
2 hours at room temperature. The solution is evaporated in vacuo to an oil and the substance is precipitated in water.
Yield: 86%
TLC: Rf = 0.55 (Pi)
3) Ac-lle-Thr-Glv-Lvs-pNA-HCI Molecular weight = 616.13
10 ml triflic acid is added to a cold (-10°C) suspension of 1 mmol α-Ac-lle-O- Bzl-Thr-Gly-ε-Z-Lys-pNA (3c) in 10 ml methylenchloride. The mixture is stirred for 50 minutes at room temperature and precipitated with diethylether. The product is ion exchanged and purified in the same way as in example 1. Yield: 36%
Figure imgf000013_0001
HPLC: 97% purity r α] 25 = -53.2° (c= 0.3%) D
Example 4
α-Ac-lle-Glu-Glvc-Arq-pNA-HCI Molecular weight = 673.18
4a) GIvc-Arφ-pNA-HCl Molecular weight: = 388.8
5 mmol Arg-pNA-2 HBr dissolved in 30 ml DMF is neutralized in cold (-10°C) with Et3N. To the solution 5 mmol glycolic acid, 5 mmol HOBT and 5.1 mmol DCCI are added. The mixture is stirred for 1 hour in cold and 72 hours at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil, which is purified on a Sephadex® QAE-25 column in chloride form with 90% ETOH as eluent.
Yield: 74%
TLC: Rf = 0.35 (A).
4b) α-Boc-v-O-Bzl-Glu-Glvc-Arg-pNA-HCI Molecular weight = 708.2
To 5 mmol Glyc-Arg-pNA-HCI dissolved in 30 ml DMF and cooled to -10°C, 5 mmol α-Boc-γ-O-Bzl-Glu-OH, 5 mmol HOBT, 0.5 mmol DMAP and 5.1 mmol
DCCI are added. The mixture is stirred for 1 hour in cold and 48 hours at room temperature. The formed DCU is filtered off and the solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHCθ3, 2%
KHSO4 and H20. After drying with Na2S04, the EtOAc is evaporated and the substance is precipitated with diethylether.
Yield: 66%
TLC: Rf = 0.35 (Pa6).
4c) α-Boc-lle-γ-0-Bzl-Glu-Glvc-Arg-pNA-HCl Molecular weight = 821.3
10 ml TFA is added to 2 mmol α-Boc-γ-O-Bzl-Glu-Glyc-Arg-pNA-HCI (4b) dissolved in 20 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethyleter. The dry substance is dissolved in 25 ml DMF and neutralized in cold (-10°C) with Et3 . To the solution 2 mmol α-Boc-lle-ONp is added. The mixture is stirred for 1 hour in cold and 48 hours at room temperature. The solution is evaporated in vacuo to an oil which is dissolved in EtOAc and washed with 2% NaHC03, 2% KHSO4 and H2O. After drying with Na24 the EtOAc phase is evaporated and the substance is precipitated with diethylether.
Yield: 69%
TLC: Rf = 0.43 (Pa6)
4d) α-Ac-lle-γ-O-Bzl-Glu-Glvc-Arq-pNA-HCI Molecular weight = 763.3
5 ml TFA is added to 1 mmol α-Boc-lle-γ-O-Bzl-Glu-Glyc-Arg-pNA-HCI (4c) dissolved in 10 ml methylenchloride. The mixture is stirred for 30 minutes at room temperature and the substance is precipitated with diethylether. The dried substance is dissolved in 10 ml DMF and neutralized in cold (-10°C) with 130 μ!
EtβN. 120 μl acetic anhydride is added and the mixture is stirred for 1 hour in cold and 2 hours at room temperature. The solution is evaporated in vacuo to an oil and the substance is precipitated with H2O.
Yield: 94%
TLC: Rf = 0.34 (Pa6).
4 α-Ac-lle-Glu-Glvc-Arα-pNA-HCI Molecular weight = 673.18
10 ml triflic acid is added to a cold (-10°C) suspension of 1 mmol α-Ac-lle-γ-O- Bzl-Glu-Glyc-Arg-pNA-HCI (4d) in 10 ml methylenchloride. The mixture is stirred for 50 minutes at room temperature and precipitated with diethylether. The substance is ion exchanged and purified in the same way as in example 1. Yield: 31% TLC: Rf = 0.45 (A) HPLC: 98% purity [ a ] 25 = -60.6° (c= 0.4%) D
Comparison of the chromogenic substrates using a single-stage chromogenic LAL-test.*
A series of endotoxin containing solutions, making up a standard curve in the range 0.1-1.2 EU/ml, were assayed as described below using the different chromogenic substrates. The slopes of the resulting standard curves were compared and the slope for the substrate S-2423 was considered to be 100%.
A reagent (100 μl) consisting of a mixture of LAL (50% of the clotting concentration) and the chromogenic substrate (4.4 mM) in a Tris buffer of pH 7.9 is added to an equal volume of the sample. The resulting reaction (activation of the LAL and the subsequent hydrolyses of the chromogenic substrate) is carried out at 37°C. After 15 min. the reaction is terminated by the addition of 400 μl of acetic acid and the absorbance is read at 405 nm.
*) Limulus Ameboec te Lysate (H.C. Hemker Loc. cit.) Table I shows the results for the activated LAL with substrates as measured by the concentration of hydrolized pNA. Substrate S-2423 (Ac-lle-Glu-Gly-Arg- pNA-HCl) is taken as standard.
Table I
Screening of substrate for single stage method - endotoxin with substrate concentration 2.2 mM (in the reaction solution).
So = 2.2 mM
Figure imgf000016_0001
This table clearly shows that when using -Gly-Lys or Glyc-Arg as carboxy terminal sequence in the substrate, the activity is surprisingly considerably higher than when the known substrate S-2423, which has Gly-Arg as carboxyterminal sequence, is used.

Claims

CLAIMS.
1. Peptide derivatives, characterized by the following formula:
Ri -A-i -A2 -A3 -A4 -R2 or its salt where
R*ι = H or a protective group A1 = H, He, Leu or Val A2 = Glu, Asp, Ser, Thr A3 = Gly or Glyc A4 = Arg or Lys R2 = 4-nitro aniline with the proviso that A3 is Gly when A4 is Lys and that A3 is Glyc when A4 is Arg.
2. Peptide derivatives according to claim 1 , characterized by that A1 is He.
3. Peptide derivative according to claim 1 , characterized by that it is chosen from: alpha-Ac-lle-Glu-Gly-Lys-pNA alpha-Ac-lle-Ser-Gly-Lys-pNA alpha-Ac-lle-Thr-Gly-Lys-pNA or alpha-Ac-lle-Glu-Glyc-Arg-pNA.
4. Process for the preparation of peptide derivatives according to any of claims 1-3, characterized in that the synthesis is performed by step-by-step addition of the amino acids at the C-terminal amino acid provided with a marker.
5. Process for the preparation of peptide derivatives according to any of claims 1-3, characterized in that the synthesis is performed by synthesis of the N-terminal peptide fragment per se, which then is coupled to the C-terminal amino acid provided with a marker.
6. Method for determination of bacterial endotoxins, characterized by the use of peptide derivates with the following formula:
R1 - A-i - A2 - A3 - A4 - R2 or its salt where R1 = H or a protective group Ai = H, He, Leu or Val
A2 = Glu, Asp, Ser, Thr
A3 = Gly or Glyc
A4 = Arg or Lys
R2 = an aromatic or heterocyclic group which gives the compound
R2-NH2 by enzymatic hydrolysis, which can be determined quantitatively, with the proviso that when A3 is Gly when A4 is Lys and that A3 is Glyc when A4 is Arg.
7. Method for determination of bacterial endotoxins, characterized by the use of peptide derivatives according to claim 6 in which A1 is He.
8. Method for determination of bacterial endotoxins, characterized by the use of peptide derivatives according to claim 6 chosen from: alpha-Ac-lle-Glu-Gly-Lys-pNA alpha-Ac-lle-Ser-Gly-Lys-pNA alpha-Ac-lle-Thr-Gly-Lys-pNA or alpha-Ac-lle-Glu-Glyc-Arg-pNA.
9. Method for determination of bacterial endotoxins, characterized by the use of peptide derivatives according to claim 6 in which NH2-R2 is a chromogenic group.
10. Use of any of the peptide derivatives according to any of claims 1 -3 for determination of bacterial endotoxins.
PCT/SE1990/000797 1989-12-12 1990-12-03 Chromogenic substrate Ceased WO1991009052A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
DE69030102T DE69030102T2 (en) 1989-12-12 1990-12-03 CHROMOGENIC SUBSTRATE
JP3501386A JP2929555B2 (en) 1989-12-12 1990-12-03 Chromogenic substrate
US07/859,717 US5334703A (en) 1989-12-12 1990-12-03 Chromogenic substrate
EP91900986A EP0505428B1 (en) 1989-12-12 1990-12-03 Chromogenic substrate

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8904188-3 1989-12-12
SE8904188A SE8904188D0 (en) 1989-12-12 1989-12-12 CHROMOGENIC SUBSTRATE

Publications (1)

Publication Number Publication Date
WO1991009052A1 true WO1991009052A1 (en) 1991-06-27

Family

ID=20377747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1990/000797 Ceased WO1991009052A1 (en) 1989-12-12 1990-12-03 Chromogenic substrate

Country Status (9)

Country Link
US (1) US5334703A (en)
EP (1) EP0505428B1 (en)
JP (1) JP2929555B2 (en)
AT (1) ATE149516T1 (en)
AU (1) AU6957991A (en)
DE (1) DE69030102T2 (en)
ES (1) ES2098344T3 (en)
SE (1) SE8904188D0 (en)
WO (1) WO1991009052A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571683A (en) * 1991-12-25 1996-11-05 Maruha Corporation β-glucans detection reagents and methods of detecting β-glucans

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10251894A1 (en) * 2002-11-07 2004-05-19 C-Cit Ag New peptide-containing benzophenoxazine or napthoquinone derivatives, useful as chromogenic substrates for enzymes, e.g. for diagnosis, monitoring therapy and detecting pyrogens
EP4709877A2 (en) * 2023-05-12 2026-03-18 Life Technologies Corporation Methods and kits for detecting endotoxin

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244865A (en) * 1979-12-03 1981-01-13 Abbott Laboratories α hydroxy tripeptide substrates
WO1982000641A1 (en) * 1980-08-25 1982-03-04 Ab Kabivitrum Peptide substrates for determination of protease activity
WO1982002382A1 (en) * 1981-01-09 1982-07-22 Monsigny Michel Method for the fluorometric determination of endotoxins,new peptides carrying a fluorophorous substance usable in said method and method for its preparation
EP0080649A1 (en) * 1981-11-16 1983-06-08 Seikagaku Kogyo Co. Ltd. Method for determining bacterial endotoxin and kit therefor
WO1983002123A1 (en) * 1981-12-17 1983-06-23 SÖDERHÄLL, Kenneth, Tord METHOD AND REAGENT FOR DETECTION OF ENDOTOXINES OR 'beta'-1,3 GLUCANES FROM FUNGUS OR BACTERIA
EP0110306A2 (en) * 1982-11-27 1984-06-13 BEHRINGWERKE Aktiengesellschaft Chromogene compounds, process for their preparation and their use
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3759218A (en) * 1971-08-03 1973-09-18 H Korstvedt Breading apparatus
JPS5415797A (en) * 1977-06-14 1979-02-05 Seikagaku Kogyo Co Ltd Detection and measurement of toxin in cells
SE7801373L (en) * 1978-02-07 1979-08-08 Kabi Ab EASY SPLABLE SUBSTRATE FOR QUANTIFIATION OF PROTEASES
US4510241A (en) * 1981-09-03 1985-04-09 Mallinckrodt, Inc. Peptide-type substrates useful in the quantitative determination of endotoxin
JPS62236474A (en) * 1986-04-08 1987-10-16 San Plant Kogyo Kk Flour attaching automatic machine
JPS62294027A (en) * 1986-06-11 1987-12-21 サン・プラント工業株式会社 Roller type powder feeder

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244865A (en) * 1979-12-03 1981-01-13 Abbott Laboratories α hydroxy tripeptide substrates
WO1982000641A1 (en) * 1980-08-25 1982-03-04 Ab Kabivitrum Peptide substrates for determination of protease activity
US4563305A (en) * 1981-01-07 1986-01-07 University Of Miami Radiolabelled substrates for assaying mammalian enzymes
WO1982002382A1 (en) * 1981-01-09 1982-07-22 Monsigny Michel Method for the fluorometric determination of endotoxins,new peptides carrying a fluorophorous substance usable in said method and method for its preparation
EP0080649A1 (en) * 1981-11-16 1983-06-08 Seikagaku Kogyo Co. Ltd. Method for determining bacterial endotoxin and kit therefor
WO1983002123A1 (en) * 1981-12-17 1983-06-23 SÖDERHÄLL, Kenneth, Tord METHOD AND REAGENT FOR DETECTION OF ENDOTOXINES OR 'beta'-1,3 GLUCANES FROM FUNGUS OR BACTERIA
EP0110306A2 (en) * 1982-11-27 1984-06-13 BEHRINGWERKE Aktiengesellschaft Chromogene compounds, process for their preparation and their use

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571683A (en) * 1991-12-25 1996-11-05 Maruha Corporation β-glucans detection reagents and methods of detecting β-glucans

Also Published As

Publication number Publication date
DE69030102T2 (en) 1997-07-17
EP0505428A1 (en) 1992-09-30
AU6957991A (en) 1991-07-18
JPH05506209A (en) 1993-09-16
EP0505428B1 (en) 1997-03-05
SE8904188D0 (en) 1989-12-12
ATE149516T1 (en) 1997-03-15
ES2098344T3 (en) 1997-05-01
DE69030102D1 (en) 1997-04-10
US5334703A (en) 1994-08-02
JP2929555B2 (en) 1999-08-03

Similar Documents

Publication Publication Date Title
US3884896A (en) New substrates for diagnostic use, with high susceptibility to thrombin and other proteolytic
EP0004256B1 (en) Easily split substrates for the quantification of proteases, a process for their production and a method for the quantification of proteases
EP0000063B1 (en) Dipeptide derivatives of 7-(n-alpha-substituted or non-substituted x-arginyl)-amino-4-methyl-coumarin
Taylor Ynthesis of
US4138394A (en) Peptide derivatives and a method of measuring collagenase activity
GB2028342A (en) Peptides derivatives of 4-methylcoumarin
US4244865A (en) α hydroxy tripeptide substrates
EP0505428B1 (en) Chromogenic substrate
DK145799B (en) TRIPEPTIDES OR SALTS THEREOF USED AS DIAGNOSTIC CHROMOGENT SUBSTRATE WITH HIGH SPECIFICITY ABOVE THROMBIN AND THROMBIN SIMILAR ENZYMES
US4176009A (en) Method of measuring collagenase activity
JP2887765B2 (en) Symmetric bipeptides containing polyalkylene glycol residues, methods for their preparation and use in protease assays
US4797472A (en) New peptide derivatives
US4369137A (en) N-Protected pentapeptides useful as intermediates in the preparation of thymopoietin pentapeptide
US5097014A (en) Chromogenic tripeptides
US4569907A (en) Thiopeptolide substrates for vertebrate collagenase
JP2896605B2 (en) New peptide substrates, preparation methods and uses in protein C determination
US3655636A (en) Process for the synthesis of peptides using 4-pyridylmethyl and related groups for the protection of c-terminal carboxyl groups
EP0262191B1 (en) Novel peptide derivatives
US4474691A (en) Chromophoric peptides, a process for their preparation, agents containing them and their use for determining DD-carboxypeptidases
Hamburger et al. Peptidyl-tRNA: XI. The chemical synthesis of phenylalanine-containing oligopeptidyl-tRNA
JP2890330B2 (en) Peptide substrate for identifying factor Xa
US3640991A (en) Mixed anhydride method of preparing peptides
DK171845B1 (en) Tripeptide derivatives and a process for preparing them, and a process for determining serine proteases or components which can co-operate with serine proteases
US4596675A (en) Novel thiopeptolide substrates for vertebrate collagenase
US5362851A (en) Peptide substrates, method of preparation and use in the determination of protein C

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1991900986

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991900986

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1991900986

Country of ref document: EP